Exelixis
Clinical trials sponsored by Exelixis, explained in plain language.
Oncology-focused biopharmaceutical company developing cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug XB010 takes on advanced cancers in first human trial Results expected Nov 2026 (estimated)
- Can a drug combo outperform standard therapy for a rare kidney cancer? Results expected Dec 2026 (estimated)
- New drug combo aims to shrink hard-to-treat tumors Results expected Jan 2027 (estimated)
- New hope for Hard-to-Treat cancers? early trial launches Results expected May 2027 (estimated)
-
Brain tumor drug trial halted before results
Disease control Stopped earlyThis study tested the drug cabozantinib in 19 people with a severe type of brain tumor (grade IV astrocytic tumors) that had come back after initial treatment. The goal was to see if the drug could shrink tumors or slow progression. However, the company stopped the trial early fo…
Phase 2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Promising prostate cancer combo trial halted before results
Disease control Stopped earlyThis phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for busine…
Phase 2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC